New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes using basal insulin (≥42 units/day) plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: EDITION 2 was a multicenter, open-label, two-arm study. Adults receiving basal insulin plus OADs were randomized to Gla-300 or Gla-100 once daily for 6 months. The primary end point was change in HbA1c. The main secondary end point was percentage of participants with one or more nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events from week 9 to month 6. RESULTS: Randomized participants (n = 811) had a mean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg/m2 (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was −0.57% (0.09) for Gla-300 and −0.56% (0.09) for Gla-100 (mean difference −0.01% [95% CI −0.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61–0.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified. CONCLUSIONS: Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but about 7% to 15% of insulin-treated persons with T2D experience at least 1 episode of hypoglycemia per year,1109 and 1% to 2% have severe hypoglycemia.1106,1108”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“Hypoglycemia and weight gain are the most common adverse effects of insulin therapy.1106,1107”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered (179-181).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [181]
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615 · cited 1×
“5 rapidly progressing diabetic retinopathy (which may likely require laser/surgical treatment during the study), end-stage renal disease (defined as those participants requiring dialysis or transplantation (12)), or clinically significant cardiac, hepatic, or other systemic disease.”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“3 Insulin glargine 100 U/mL (Gla-100) is a once-daily, long-acting basal insulin analog, which induces less hypoglycemia than neutral protamine Hagedorn (NPH) insulin (1).”
BackgroundSelf-citationDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“adherence to the treatment regimen (7,8).”
Psychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 2×
“After subcutaneous injection, Gla-300 has been shown to have smoother, more stable, and prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100, resulting from an extended release of glargine from the subcutaneous depot (9).”
BackgroundRiddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Self-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
BackgroundInsulin detemir: from concept to clinical experience
Home, P., & Kurtzhals, P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.325 · Cited by 139 · cited 1×
“This finding is consistent with results of EDITION 1, where the magnitude was comparable with that observed previously in studies comparing glargine and detemir insulins (16,17).”
ResultKurtzhals, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802746 · Cited by 118 · cited 1×
“This finding is consistent with results of EDITION 1, where the magnitude was comparable with that observed previously in studies comparing glargine and detemir insulins (16,17).”
ResultBergenstal, R. M., Rosenstock, J., Arakaki, R. F., Prince, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2012) · Diabetes Care · doi:10.2337/dc12-0060 · Cited by 115 · cited 1×
“degludec and glargine 100 U/mL (14) and those comparing PEGylated insulin lispro (LY2605541) and glargine 100 U/mL (15).”
BackgroundSelf-citationAschner, P. J., Chan, J. C. N., Owens, D. R., Picard, S., Wang, E., Dain, M., Pilorget, V., Echtay, A. S., & Fonseca, V. A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60439-5 · Cited by 115 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
BackgroundBolli, G. B., Andreoli, A. M., & Lucidi, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0039 · Cited by 33 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
BackgroundThe ORIGIN Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2238 · Cited by 28
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Metadata
- Authors
- Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C.
- Affiliations
- Department of Medicine, University of Helsinki, and Minerva Foundation Institute for Medical Research, Helsinki, Finland
- Park Nicollet Health Services (US)
- Sanofi (Germany) (DE)
- Sanofi, Warsaw, Poland
- Sanofi, Paris, France
- Oregon Health & Science University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-11-08
- Volume
- 37
- Issue
- 12
- Pages
- 3235-3243
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4230570152
- Cited by
- 274
- References
- 17
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 19 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 47 · 2017: 33 · 2016: 40 · 2015: 23 · 2014: 2
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, type 2 diabetes, basal insulin, oral antidiabetic drugs, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain, insulin dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.